Isopropyl Myristate

Isopropyl Myristate

SCHEMBL1724352

CCCCCCCCCCCCCC(=O)O.CCCCCCCCCCCCCC(=O)OC(C)C

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.85
GPR84 Q9NQS5 7/20 0.63
PPARG P37231 7/20 0.63
PPARD Q03181 7/20 0.63
PPARA Q07869 7/20 0.63
HDAC11 Q96DB2 5/20 0.63
TSHR P16473 4/20 0.63
PTPN1 P18031 3/20 0.63
ALDH1A1 P00352 2/20 0.63
TLR2 O60603 2/20 0.63
TDP1 Q9NUW8 2/20 0.63
FABP4 P15090 2/20 0.63
KMT2A Q03164 2/20 0.63
FFAR4 Q5NUL3 2/20 0.63
SLC22A6 Q4U2R8 1/20 0.63
SLC22A8 Q8TCC7 1/20 0.63
MEN1 O00255 1/20 0.63
ESR1 P03372 1/20 0.63
ALOX15 P16050 1/20 0.63
PDE4A P27815 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dodecanoate SCHEMBL31753491 1.00 LMNA (0.85) LMNAGPR84PPARGPPARDPPARA
Isopropyl Palmitate SCHEMBL1692109 1.00 LMNA (0.85) LMNAGPR84PPARGPPARDPPARA
Isopropyl Myristate SCHEMBL31281067 1.00 LMNA (0.85) LMNAGPR84PPARGPPARDPPARA
Palmitic Acid SCHEMBL6135487 1.00 LMNA (0.85) LMNAGPR84PPARGPPARDPPARA
Isopropyl Palmitate SCHEMBL8509050 1.00 LMNA (0.85) LMNAGPR84PPARGPPARDPPARA
Isopropyl Palmitate SCHEMBL8566831 1.00 LMNA (0.85) LMNAGPR84PPARGPPARDPPARA
Isopropyl Myristate SCHEMBL1868588 1.00 LMNA (0.85) LMNAGPR84PPARGPPARDPPARA
Isopropyl Myristate SCHEMBL16399923 1.00 LMNA (0.85) LMNAGPR84PPARGPPARDPPARA
Myristic Acid SCHEMBL10535750 1.00 LMNA (0.85) LMNAGPR84PPARGPPARDPPARA
Octanoic Acid SCHEMBL28941825 1.00 LMNA (0.85) LMNAGPR84PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630398-A1 N-ACYL AMINOALKANE SULFONATE SURFACTANTS AND DERIVATIVES THEREOF The Procter & Gamble Company (US) 2025-10-15 EP disclosed
US-20240209282-A1 N-ACYL AMINOALKANE SULFONATE SURFACTANTS AND DERIVATIVES THEREOF THE PROCTER & GAMBLE COMPANY 2024-06-27 US disclosed
EP-4351512-A1 BLENDS OF N-ACYL ALANINATES AND OTHER N-ACYL AMINO ACID SURFACTANTS AND DERIVATIVES THEREOF The Procter & Gamble Company (US) 2024-04-17 EP disclosed
EP-4352189-A1 N-ACYL AMINO ACID SURFACTANTS AND DERIVATIVES THEREOF The Procter & Gamble Company (US) 2024-04-17 EP disclosed
US-11931452-B2 Topical compositions containing rofecoxib and methods of making and using the same JF PHARMA TECH LLC (US) 2024-03-19 US disclosed
CN-116601139-A N-acyl amino acid surfactant and derivatives thereof 宝洁公司 2023-08-15 CN disclosed
CN-116472025-A Blends of N-acyl alanine salts and other N-acyl amino acid surfactants and derivatives thereof 宝洁公司 2023-07-21 CN disclosed
CN-115916183-A Topical compositions containing rofecoxib and methods of making and using the same 布里奥里生物技术公司 2023-04-04 CN disclosed
US-20220401328-A1 N-ACYL AMINO ACID SURFACTANTS AND DERIVATIVES THEREOF THE PROCTER & GAMBLE COMPANY 2022-12-22 US disclosed
US-20220403291-A1 BLENDS OF N-ACYL ALANINATES AND OTHER N-ACYL AMINO ACID SURFACTANTS AND DERIVATIVES THEREOF THE PROCTER & GAMBLE COMPANY 2022-12-22 US disclosed
US-11260023-B2 Topical compositions containing rofecoxib and methods of making and using the same BRIORI BIOTECH, LLC (US) 2022-03-01 US disclosed
US-20210220259-A1 TOPICAL COMPOSITIONS CONTAINING ROFECOXIB AND METHODS OF MAKING AND USING THE SAME ESTRATO PHARMA INC 2021-07-22 US disclosed
WO-2020022634-A1 LIQUID CRYSTAL EMULSION COMPOSITION FOR SHEET MASK, PREPARATION METHOD THEREFOR, AND SHEET MASK COMPRISING SAME 주식회사 리더스코스메틱 2020-01-30 WO disclosed
CN-101278668-B Evaporation device SUMITOMO CHEMICAL CO 2011-10-05 CN disclosed
EP-2344531-A1 MODIFIED VARIANT BOWMAN BIRK PROTEASE INHIBITORS Danisco US Inc. (US) 2011-07-20 EP disclosed
WO-2010117740-A2 ENHANCED FORMULATIONS, COMPOSITIONS AND METHODS FOR PEST CONTROL TYRATECH, INC. (US) 2010-10-14 WO disclosed
WO-2010044786-A1 MODIFIED VARIANT BOWMAN BIRK PROTEASE INHIBITORS DANISCO US INC., GENENCOR DIVISION (US) 2010-04-22 WO disclosed
WO-2008122421-A1 PEARLESCENT PIGMENTS CONTAINING COSMETIC COMPOSITIONS ECKART GMBH (DE) 2008-10-16 WO disclosed
CN-101278668-A Evaporation device SUMITOMO CHEMICAL CO (JP) 2008-10-08 CN disclosed
US-5817155-A WATER IN OIL, POLAR OIL, PHASE INVERSION OR DEMULSIFICATION SHISEIDO CO., LTD. (JP) 1998-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220401328-A1 N-ACYL AMINO ACID SURFACTANTS AND DERIVATIVES THEREOF SLC38A7, ASNS, SLC6A15 LMNA 1008/4885GPR84 2544/4885PPARG 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.